Our in-house proprietary protocol is established to develop, design and optimize DNA sequences for vaccine development, providing a standardized and scalable platform for the continued development of DNA vaccine products.

We believe it is an effective way for leveraging resources that we own our strong CMC processes to ensure the production of DNA vaccine with world class quality, purity and yield. 

The purity of supercoiled pDNA we manufactured can reach more than 97% compared to FDA standards of 85%. Through next-generation processes and testing technologies, we are able to achieve high recovery rates for plasmid production and ensure the high quality of our vaccine products. Comparing to many other vaccine technologies, DNA vaccines have a key competitive advantage of the ability to stimulate both B cells and T cells, which generally translates to a strong immune response.

Through our years of knowledge and experience build-up in protein design and identification, particularly in combination with adjuvants, we have developed a profound understanding of protein structure and profiles in different viruses. This has enabled us to better develop vaccine products that target or utilize specific proteins and that are used in combination with adjuvants to enhance immunogenicity. We have developed an E. coli-based expression system, which enables high expression of proteins, and in turn translates to better immunogenicity of our vaccine candidates.

Moreover, using E. coli as host is more cost-effective compared to cell culture systems used by many major vaccine development platforms. Our protein subunit vaccine manufacturing process includes innovative extraction and purification technologies that ensures a high purity level for certain difficult-to-produce proteins. Moreover, our protein subunit vaccine manufacturing process is streamlined and robust, which is suitable for efficient scale-up for commercial production.

Traditionally, adjuvants are used in conjunction with vaccines to help the host’s immune system to recognize the pathogen and amplify the magnitude of immunoresponse against the pathogen. We have developed innovative adjuvants that not only enhance CD8+ cytotoxic T cell functions, but also can act as immunomodulators to induce Treg cells to control overreactive T cells. Our adjuvant platform primarily includes three key technologies, namely, adjuvant in vitro screening system, cell-guided adjuvant screening and adjuvancity animal test. By applying these technologies in sequence, we are able to screen, analyze and evaluate potential adjuvants for particular purposes with speed and accuracy.